clinical trial · NCT07473843
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial HypercholesterolemiaZodasiran
brief summary
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.
started
Aug 1, 2026
primary completion
Jul 1, 2028
completion
Aug 1, 2028
last updated
May 29, 2026
official title
Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Participants (Age 12 to <18 Years) With Homozygous Familial Hypercholesterolemia (SPRUCE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol